The Eeva™ Test is CE Marked and is commercially available in select EU countries.

CAUTION – Investigational device. Limited by United States law to investigational use.

Eeva (Early Embryo Viability Assessment) is a non-invasive test designed to improve in vitro fertilization (IVF) outcomes by providing quantitative and objective information on the early stages of the embryo’s development. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters and classifies each embryo as either “High” or “Low”, providing the embryologist with a predictive score about the embryo’s viability to use in conjunction with traditional morphology.

The Eeva Test was developed based on landmark research1 conducted at Stanford University, which discovered that early cell division events can predict embryo developmental outcome and reflect the underlying molecular health of the embryo. The research measured the time it took each embryo to achieve specific cell development milestones during the first two days after fertilization in vitro. This led to the discovery of precise cell-division timing parameters that could non-invasively help embryologists predict on Day 3 which embryos were most likely to develop to blastocyst stage.

> Clinical Studies

Auxogyn, Inc, the company behind the Eeva test, is enrolling patients in clinical studies on an ongoing basis. Information about the details of each of these studies can be found here.

1 Wong et al. Nature Biotechnology (2010)

Learn about the Eeva (MERGE) Research Study